Major depressive disorder (MDD) is characterized by persistent depressed mood, loss of
interest or pleasure in previously enjoyable activities, recurrent thoughts of death, and …

Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify
and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are …

A high proportion of depressed patients fail to respond to antidepressant drug treatment.
Treatment‐resistant depression (TRD) is a major challenge for the psychopharmacology of …

Background In recent years, ketamine and esketamine treatment have demonstrated rapid
antidepressant effects in adults with treatment-resistant depression (TRD). Hitherto …

Major depressive disorder (MDD) affects millions of individuals worldwide, leading to
considerable social and economic costs. Despite advancements in pharmacological …

Aim: Chaihu-jia-Longgu-Muli-tang (CLM) is derived from “Shang Han Lun” and is
traditionally prescribed for treating depression. However, there is still a lack of evidence for …

Background Previous studies suggest that transcranial magnetic stimulation exerts
antidepressant effects by altering functional connectivity (FC). However, knowledge about …

Background: Stressful events increase the risk for treatment-resistant depression (TRD), and
trauma-focused psychotherapy can be useful for TRD patients exposed to early life stress …

Childhood maltreatment increases risk for mood disorders and is associated with earlier
onset—and more pernicious disease course following onset—of mood disorders. While the …

Glutamate release and reuptake play a key role in the pathophysiology of depression.
glutamatergic nerves in the hippocampus region are modulated by histaminergic afferents …